New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)

Simply Wall St.07-19 19:16

Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652211251?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-19 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652211251","market":"hk","top_or_hot":-1,"title":"New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)","media":"Simply Wall St.","content":"<div>\n<p>Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/new-lupkynis-combo-study-in-lupus-nephritis-might-change-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-19 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/new-lupkynis-combo-study-in-lupus-nephritis-might-change-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/new-lupkynis-combo-study-in-lupus-nephritis-might-change-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/new-lupkynis-combo-study-in-lupus-nephritis-might-change-the","article_id":"2652211251","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/new-lupkynis-combo-study-in-lupus-nephritis-might-change-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652211251","pubTimestamp":1784459765,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint.\nThis post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"狼疮性肾炎的新 LUPKYNIS Combo 研究可能会改变投资 Aurinia (AUPH) 的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1.5},"content_text":"Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint. This post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months, potentially broadening its role in combination regimens. We’ll now examine how this new Phase 4 combination study for LUPKYNIS may influence Aurinia’s investment narrative and future growth drivers. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementAurinia Pharmaceuticals Investment Narrative RecapTo own Aurinia, you need to believe LUPKYNIS can sustain its position in lupus nephritis while management carefully manages concentration risk in a single commercial asset. The PRESERVE Phase 4 combination study reinforces LUPKYNIS’s clinical profile, but its near term effect on the key catalyst short term revenue and prescription trends appears limited, while dependence on one drug and ongoing exclusivity and Paragraph IV questions remain the central risk. Among recent updates, the AURORA 1 Phase 3 data presented at EULAR 2026 looks most connected to PRESERVE. Those results, showing reduced renal related events and death in LUPKYNIS treated patients, strengthen the clinical rationale for testing combinations with belimumab, obinutuzumab, and anifrolumab. Together, AURORA 1 outcomes and PRESERVE could shape how durable LUPKYNIS’s role is in treatment algorithms, which matters for how investors think about future revenue resilience. Yet in contrast to the bullish data points, investors should be aware that Aurinia’s reliance on a single marketed drug still leaves them exposed to... Read the full narrative on Aurinia Pharmaceuticals (it's free!)Aurinia Pharmaceuticals' narrative projects $461.3 million revenue and $176.3 million earnings by 2029. This requires 15.6% yearly revenue growth and a $121.9 million earnings decrease from $298.2 million today.Uncover how Aurinia Pharmaceuticals' forecasts yield a $17.00 fair value, a 7% upside to its current price.Exploring Other PerspectivesAUPH 1-Year Stock Price Chart While PRESERVE could eventually support a more resilient LUPKYNIS story, the most pessimistic analysts were assuming revenue of about US$406.7 million and earnings of only US$62.7 million by 2029, so you may want to weigh that more cautious view against the combination data now emerging.Explore 6 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth just $17.00!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Opportunities like this don't last. These are today's most promising picks. Check them out now:Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652211251","isCrawlerRequest":true}